| Title |
Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma
|
|---|---|
| Published in |
Annals of Surgical Oncology, August 2011
|
| DOI | 10.1245/s10434-011-2027-2 |
| Pubmed ID | |
| Authors |
S. Kruijff, E. Bastiaannet, A. H. Brouwers, W. B. Nagengast, M. J. Speijers, A. J. H. Suurmeijer, G. A. Hospers, H. J. Hoekstra |
| Abstract |
To investigate the feasibility of using bevacizumab to improve the survival of American Joint Committee on Cancer (AJCC) stage III melanoma patients, we investigated how a single bevacizumab treatment affected nodal disease and a panel of biomarkers in clinically fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT)-staged, stage III melanoma patients, prior to therapeutic lymph node dissection (TLND). |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 46% |
| Other | 2 | 8% |
| Student > Doctoral Student | 1 | 4% |
| Student > Bachelor | 1 | 4% |
| Unspecified | 1 | 4% |
| Other | 4 | 15% |
| Unknown | 5 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 42% |
| Biochemistry, Genetics and Molecular Biology | 3 | 12% |
| Agricultural and Biological Sciences | 2 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Unspecified | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 5 | 19% |